-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Initiates Coverage On Rhythm Pharmaceuticals with Outperform Rating, Announces Price Target of $145

Benzinga·02/19/2026 14:45:25
Listen to the news
RBC Capital analyst Lisa Walter initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform rating and announces Price Target of $145.